胸腺肽α_1对非小细胞肺癌化疗患者免疫功能的影响

Effects of thymosin α1 on immune function in patients with non-small cell lung cancer treated by chemotherapy

目的探讨胸腺肽α1对非小细胞肺癌(NSCLC)化疗患者免疫功能的影响。方法将2008年1月至2010年1月间收治的78例NSCLC患者随机分为两组,对照组患者38例,采用长春瑞滨+顺铂(NP方案)化疗;试验组患者40例,在对照组基础上加用胸腺肽α1,比较治疗前后两组患者免疫功能的变化。结果治疗后,试验组患者血清CD+3、CD+4、CD+4/CD+8和NK细胞明显升高,CD+8明显下降,差异均有统计学意义(均P<0.05);对照组患者血清CD+3、CD+4、CD+4/CD+8和NK细胞明显降低,CD+8明显升高,差异均有统计学意义(均P<0.05)。结论 NSCLC患者在化疗的同时应用胸腺肽α1有显著增强机体免疫功能的作用。

Objective To investigate the effects of thymosin α1 on immune function in patients with non-small cell lung cancer （NSCLC） treated by chemotherapy. Methods 78 cases of NSCLC were ran- domly divided into two groups, the control group （n = 38 ） was treated with NP chemotherapy, and the obser- vation group （n = 40） addtional thymosin α1 on base of NP therapy. Changes of immune function before and after treatment were compared between the two groups. Results After treatment,the levels of serum CD3 , CD4, CD4＋/CD8＋ and NK cells significantly increased, CDs decreased, the differences were statistically sig- nificant （ P 〈 O. 05） ; In the control group, the CD3＋ , CD4＋ , CD4/CD8＋ and NK ceils significantly decreased, CDs significantly increased, the differences were statistically significant （ P 〈 O. 05 ）. Conclusions In treatment of NSCLC, chemotherapy plus thymosin α1 can significantly enhance the immune function.